suppression. Finally, culture conditions may be developed which could be applied to gene transduction protocols.
engraftment of both neutrophils and platelets. In conTen patients received у20 × 10 4 CFU-GM/kg unmanipclusion, we feel that, CD34
+ cells, expanded ex vivo using ulated PBPC in addition to an aliquot of expanded cells the conditions described in this report, may not provide (range 33-279 × 10 4 CFU-GM/kg). There were no toxic durable engraftment following fully myeloablative effects from the progenitor cells which had been generated conditioning.
ex vivo.
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Keywords: ex vivo expansion; CD34 positive; PBPC; The primary objective of this second study was to determyeloablative chemoradiotherapy mine whether CD34 + cells expanded ex vivo would secure both short-and long-term engraftment following fully myeloablative chemo/radiotherapy. To our knowledge, this is Over the last few years, attempts have been made to expand the first report testing the ability of progenitor cells generhaemopoietic progenitor cells ex vivo. [1] [2] [3] [4] [5] [6] There are several ated ex vivo to sustain haemopoiesis following myeloablpotential clinical applications for stem cell expansion. It ative regimens. There was no attempt to reduce the starting may be possible to reduce the harvesting requirements and cell dose and the number of cells available prior to expantherefore the likelihood of tumour cell contamination. sion was variable. All four cases experienced delayed Expanded progenitor cells may be used to ameliorate panhaematological recovery and were therefore given unmacytopenia post-transplant, or to cover multiple courses of nipulated PBPC 'back-up' to secure engraftment. In one high-dose chemotherapy and so prevent cumulative myelocase, the CD34 selected, ex vivo expanded cells were contaminated during culture and contributed to infective complications following transplantation. 
Patients and methods

Recovery from liquid nitrogen and CD34 selection
In our previous study, 6 we established that PBPC can be Patient selection recovered from cryopreservation and can subsequently be CD34 selected with excellent purity, recovery and viability This small study group comprised four patients (two nonHodgkin's lymphoma (NHL), two multiple myeloma of CD34 + cells. The ability to recover cells, as required, from liquid nitrogen clearly adds a major degree of flexi-(MM)). Detailed information regarding these four patients and 10 historical controls, used for comparison, are given bility to these studies. In this study, for three patients, cryopreserved PBPC were recovered from liquid nitrogen prior in Table 1 . PBPC were collected using a COBE Spectra cell separator (Cobe, Lakewood, CO, USA) following standard to subsequent CD34 selection and ex vivo expansion. For the other patient, half of the available material was CD34 protocols. Mobilisation was performed after a myelosuppressive pulse of a chemotherapy regimen selected for selected and then cryopreserved. Both of these techniques for CD34 selection are currently in use in our unit. Eight activity against the primary disease, rather than for mobilisation purposes alone (see Table 1 ). days prior to transplantation, one bag of cryopreserved material (three cases) was thawed for CD34 selection and The numbers of units of red cells and platelets transfused were recorded along with information on intravenous antisubsequent ex vivo expansion culture. At least one bag, containing a minimum of 20 × 10 4 CFU-GM/kg, was retained biotic and antifungal usage, number of days with pyrexia Ͼ37°C and number of inpatient days. Information was colin liquid nitrogen, to be reinfused, unmanipulated, in case of delayed engraftment with expanded cells. Cells were lected for historical controls (n = 10) by examination of patient records. The study protocol was approved by the recovered from cryopreservation and were then immediately processed for CD34 selection on the Isolex Magnetic local ethical committee and informed written consent was obtained from all patients. Individual data for the four cases Cell Separation System (Isolex 50 or Isolex 300) (Baxter Healthcare, Immunotherapy Division, Newbury, UK) as per along with historical control data are shown in Tables 1  and 2 . Laboratory data are shown in Table 3 . the manufacturer's instructions.
Ex vivo expansion, harvesting, reinfusion and patient Flow cytometric analyses, progenitor cell assays and long-term bone marrow culture (LTBMC) follow-up
The methods used for cell expansion were identical to those
The numbers of CD34 + cells were estimated and progenitor cell assays were performed as described previously. 6, 12, 13 used in our previous study.
6 CD34 + cells were set up in culture at an initial concentration of 0.05×10 6 /ml in gasBriefly, both selected cells (CD34 + fraction) and ex vivo expanded cells were set up at 2.5 × 10 3 /ml in a standard permeable bags in serum-free medium supplemented with autologous serum (final concentration 5-10%) and a cytomethyl cellulose medium supplemented with 10 ng/ml human SCF (Advanced Protein Products), 10 ng/ml human kine combination comprising stem cell factor (SCF) (10 ng/ml), IL-3 (10 ng/ml), IL-6 (20 ng/ml), IL-1␤ (10 ng/ml) GM-CSF (Life Technologies) and 2 Units/ml erythropoietin (Boehringer UK). Duplicate aliquots of 1 ml were plated (all purchased from Advanced Protein Products, Brockmoor, Brierly Hill, UK) and erythropoietin (2 units/ml, out into 35-mm suspension culture dishes (Nunclon; Life Technologies, Paisley, UK) and cultured for 18 days at Boehringer UK, Lewes, UK). Cultures were incubated flat for 8 days at 37°C in 5% CO 2 in a fully humidified atmos-37°C in a fully humidified atmosphere of 5% carbon dioxide. For the final case, the selected CD34 + fraction and the phere without refeeding. Following expansion culture, the cells were washed twice in phosphate-buffered saline expanded population were established in LTBMC. The cell line M2-10B4 6 was used to generate preformed stromal (PBS)/1% human serum albumin (HSA). An aliquot was then taken for analysis, including bacteriology, and the cells layers, which when confluent were irradiated with 60 Gy at a dose rate of 2 Gy/min. Irradiated stroma were mainwere reinfused following completion of chemoradiotherapy. The patients were managed by standard institained in McCoy's medium (Life Technologies) supplemented with 12.5% fetal bovine serum (Globepharm, tutional protocols except that, in addition, the first three patients received G-CSF (5 g/kg/day) at least 4 h prior to Esher, UK), 12.5% horse serum (Life Technologies), and 10 −6 m hydrocortisone (Sigma-Aldrich, Poole, UK). CD34 stem cell infusion until neutrophils recovered to у0.5 × 10 9 /l. Since G-CSF administration did not appear selected cells were reseeded onto irradiated stroma at 1 × 10 5 per culture. The number of expanded cells to have accelerated neutrophil recovery when used from the day of transplant for the first three cases, growth factor was inoculated onto stroma was adjusted for the degree of cell expansion that had taken place over the 8 days of culture. not given to the fourth case immediately after cell infusion. All cultures were set up in duplicate flasks. Cultures were (у0.5 × 10 9 /l by day 11 following infusion of back-up cells, Figure 1a ) but platelet engraftment was delayed maintained by weekly demi-depopulation. The supernatant cells were set up in the standard CFU-GM assay.
( Figure 2a) . Although a dose of 6.8 × 10 4 CFU-GM/kg was considered to be low, it was within the range of progenitor doses transplanted in the study by Brugger et al. 5 In view of the doubt concerning the adequacy of this transplant, Results no conclusion can be drawn regarding the failure of engraftment in this case. In the first case, recovery of PBPC from cryopreservation and CD34 selection resulted in excessive cell losses
The second case had been heavily pretreated, including an autograft procedure in 1994 (BEAM conditioning, Table because of cell clumping. Consequently, the selected cells expanded poorly in culture. Fourteen days post-transplant, 1) and was therefore likely to show delayed haematological recovery. Despite a fully adequate CFU-GM dose of there was no evidence of engraftment. The inadequacy of the transplanted material was corroborated by the CFU-GM 1033 × 10 4 /kg in the expanded material, early neutrophil engraftment was not maintained and platelets did not culture data, which indicated that the dose administered was only 6.8 × 10 4 CFU-GM/kg. Consequently, the patient was recover. The pattern of neutrophil recovery for this case is shown in Figure 1b . Despite continuation of daily G-CSF, given back-up unmanipulated PBPC (dose 20 × 10 4 CFU-GM/kg). Thereafter, neutrophil recovery was prompt the neutrophil count, which had reached 1.6 × 10 9 /l by day 25, fell to 0.5 × 10 9 /l over a period of only 2 days. G-CSF g/m 2 ). The third case developed pyrexia and rigors immediately after infusion of the cultured cells. Forty-eight hours was discontinued on day 27. The neutrophil count remained low for 7 further days, at which point unmanipulated PBPC later, bacteriology of the expanded cells and a blood culture confirmed a positive culture for Candida parapsillosis and were infused (104 × 10 4 CFU-GM/kg). This second cell infusion had little effect on the platelet count ( Figure 2b) the patient was commenced on parenteral amphotericin in addition to broad spectrum antibiotics. Post-expansion which did not recover to above 50 × 10 9 /l until day 82 posttransplant, however, neutrophil recovery was prompt. This CFU-GM data were not available for this case because the cultures were contaminated, however the total cell number case demonstrates that, despite extensive prior chemotherapy and a previous transplant procedure, unmanipulated did increase 7.96-fold over 8 days (Table 3) . As shown in Figure 1c , neutrophil recovery to 0.5 × 10 9 /l was achieved PBPC produced prompt neutrophil engraftment, whereas the expanded material was not able to do so.
by day 14, but after peaking at 2.4 × 10 9 /l on day 19, the count fell to 0.7 × 10 9 /l by day 24. GM-CSF was comThe third and fourth cases had received only first-line treatment for multiple myeloma prior to the transplant conmenced on day 27 , both to treat the fungal infection and to encourage neutrophil recovery. After an initial rise, the ditioning regimen. This consisted of four to six courses of 'Z-Dex' (idarubicin 10 mg/m 2 /day for 4 days, dexameneutrophil count fell and unmanipulated PBPC (295 × 10 4 CFU-GM/kg) were therefore given on day 32 for unmainthasone 40 mg/day for 4 days), a single course of DHAP (see Table 1 ) and a single course of cyclophosphamide (6 tained neutrophil and failed platelet engraftment. There-myeloablative conditioning. In murine models, in vivo studies have been used to confirm the presence of long-term repopulating cells in cell infusions, however, such studies are not possible clinically. There is, therefore, no evidence to suggest that the maintenance of LTCIC signifies the presence of cells capable of long-term reconstitution. The preparative regimen employed in the study by Brugger et al, 5 although intensive, included neither TBI nor melphalan/busulphan. Despite reinfusing suboptimal CFU-GM doses, they were still able to demonstrate prompt recovery of blood counts, not significantly different from historical controls. In our study, all four patients received fully myeloablative conditioning regimens. Although, by our standards, case 1 received an inadequate CFU-GM dose Weeks in culture Output of CFU-GM progenitors for transplantation, this dose was comparable to some of mediated by progenitor cells present in the ex vivo expanded material, while late recovery was provided by the unmanipulated PBPC given as 'back-up' in every case. This after, both neutrophils and platelets recovered. In this case, in view of the fungal contamination of the expanded provides strong evidence that, under the culture conditions used in this study, CD34 + cells expanded ex vivo may not material, it is difficult to draw definitive conclusions regarding engraftment.
contain sufficient long-term repopulating stem cells to ensure engraftment following myeloablative conditioning. The fourth case received an expanded CFU-GM dose of 157 × 10 4 /kg. A neutrophil count of 0.5 × 10 9 /l was Previous studies have reported maintenance 3 or increase 16 in the number of LTCIC following ex vivo expansion of achieved by day 19 post-transplant (Figure 1d ). However, this neutrophil count was not maintained, and there was no PBPC. Our data, though not quantitative, provide evidence that primitive progenitor cells are still present after ex vivo evidence of platelet recovery (Figure 2d) . The patient was, therefore, commenced on G-CSF (300 g/day) on day 27, culture. The apparent discrepancy between the presence of significant numbers of LTCIC and the lack of sustained followed by re-infusion of unmanipulated PBPC on day 28 (119 × 10 4 CFU-GM/kg). The neutrophil count responded engraftment may, in fact, reflect the limitations of the LTCIC assay. The LTCIC assay is clearly an in vitro to G-CSF which was continued for 7 days. Thereafter, the neutrophil count fell again until engraftment was achieved, assessment of primitive progenitor cells. In the human system, it is difficult to draw any firm conclusions about the presumably mediated by the unmanipulated cells. In all four cases, the total white count recovery mirrored the neutrorelevance of LTCIC to engraftment following myeloablative conditioning. 17 It may be dangerous to assume that phil recovery with no detectable rises in any other subset of white cells. In the fourth case, CD34-selected cells and detection of significant numbers of LTCIC equates with the presence of sufficient numbers of long-term repopulating the expanded population, were seeded into LTBMC. As shown in Figure 3 , CFU-GM output was maintained to cells (LTRC). The bi-phasic pattern of engraftment mentioned above week 5 of culture at which point the LTBMC for the CD34-selected cells became contaminated and the cultures were may not have been observed for the cases reported by Brugger et al 5 since the early phase of neutrophil terminated. CFU-GM output for the expanded cells was similar to that for the CD34-selected cells, suggesting that engraftment and the subsequent fall in neutrophils may have overlapped with endogenous neutrophil recovery from primitive progenitor cells were still present following expansion.
the high-dose, but non-myeloablative, chemotherapy used in their study. Alternatively, the culture conditions Cases 2 and 4, therefore, appear to provide very strong evidence that the progenitor cells present in the expanded employed in the two studies may have been sufficiently disparate, to produce progenitor cells with a significantly material were unable to provide sustained engraftment following the types of conditioning regimen employed in different profile of myeloid lineage commitment. However, such a direct comparison between the two studies may be this study.
inappropriate, since the patient population in Brugger's study differed in several respects from the patients reported here. Discussion
Although in vitro data suggest that long-term culture initiat 
